Deze IPO is nog niet vertaald in uw taal [en]
IMPACT THERAP-B logo

IMPACT THERAP-B

07630 · HKEX
Vermeld

Yingpai Pharmaceuticals is dedicated to tdevelopment of innovative, targeted anticproprietary intellectual property rights,focus on the synthetic lethality mechanis

Vermeld

IPO-tijdlijn

  1. OpenenMay 05
  2. SluitenMay 08
  3. ToezeggingMay 12
  4. BetalingMay 13
  5. LijstMay 13

Kerngegevens

Uitgifteprijs

HKD 20.10

Min. inschrijfkosten

HKD 4,393.86

Uitgegeven aandelen

41.98M

Lotgrootte

200

Totale verhoging

HKD 843.7M

Geschatte marktplafond

—

Overheidstoewijzing

10.0%

Internationale plaatsing

90.0%

Bedrijfsoverzicht

Yingpai Pharmaceuticals is dedicated to tdevelopment of innovative, targeted anticproprietary intellectual property rights,focus on the synthetic lethality mechanis

Gebruik van opbrengsten

1、Approximately 51% or HK$398.37 million will be allocated to fund the ongoing and planned clinical development, regulatory approval and commercialization of the core product Senaparib;

2、Approximately 31% or HK$242.15 million will be used to finance the ongoing clinical development of key products IMP1734 and IMP9064;

3、Approximately 8% or HK$62.49 million will be allocated to the R&D activities of other pipeline assets, including IMP1707, IMP7068, IMP22, IMP25, IMP08, IMP13 and IMP10;

4、Approximately 8% or HK$62.49 million will be used for the development of R&D platforms and the expansion of the pharmaceutical pipeline;

5、Approximately 2% or HK$15.62 million will be applied to working capital and other general corporate purposes.

Sponsor Track record

Track-record gegevens worden vernieuwd.

Bemiddelaars en documenten

Sponsors

  • 高盛(亞洲)有限責任公司
  • 中國國際金融香港證券有限公司

Underwriters

  • 高盛(亞洲)有限責任公司
  • 中國國際金融香港證券有限公司
  • 招銀國際融資有限公司
  • 老虎證券(香港)環球有限公司

Prospectus PDF

Prospectus PDF →

Hoeksteenbeleggers

  • 南京生物医药谷建设发展有限公司及华泰资本投资
  • 黄河投资有限公司
  • 睿远基金
  • First Quarter Moon OFC-Phecda Fund
  • LAV Star Limited
  • LAV Star Opportunities Limited
  • Prosper High Holding Limited
  • Worldwide Healthcare Partners LLC

Total

0

32.1% of placement

BBX neemt niet deel aan het toewijzingsproces voor een IPO die op deze pagina wordt vermeld. Deze pagina is uitsluitend ter informatie en is geen beleggingsadvies.